Initially built out of 20+ years of research, Glox Therapeutics has globally recognised expertise in elucidating bacteriocin structure and function and developing bacteriocin-based strategies to prevent and treat bacterial infections. The company is developing a pipeline of engineered precision bacteriocins targeting pathogens such as Pseudomonas aeruginosa and Klebsiella pneumoniae that cause serious infections associated with high levels of antimicrobial resistance (AMR) and mortality.